Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2000 1
2001 1
2007 1
2009 2
2010 1
2011 2
2012 4
2013 5
2014 8
2015 3
2016 1
2017 6
2018 6
2019 3
2020 4
2021 4
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Results by year
Filters applied: . Clear all
Page 1
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C. Vercellino L, et al. Among authors: berriolo riedinger a. Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. Blood Adv. 2020. PMID: 33180899 Free PMC article.
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Le Gouill S, Ghesquières H, Oberic L, Morschhauser F, Tilly H, Ribrag V, Lamy T, Thieblemont C, Maisonneuve H, Gressin R, Bouhabdallah K, Haioun C, Damaj G, Fornecker L, Bouhabdallah R, Feugier P, Sibon D, Cartron G, Bonnet C, André M, Chartier L, Ruminy P, Kraeber-Bodéré F, Bodet-Milin C, Berriolo-Riedinger A, Brière J, Jais JP, Molina TJ, Itti E, Casasnovas RO. Le Gouill S, et al. Among authors: berriolo riedinger a. Blood. 2021 Apr 29;137(17):2307-2320. doi: 10.1182/blood.2020008750. Blood. 2021. PMID: 33211799 Free article.
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M. Casasnovas RO, et al. Among authors: berriolo riedinger a. Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15. Lancet Oncol. 2019. PMID: 30658935 Clinical Trial.
Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.
Berriolo-Riedinger A, Becker S, Casasnovas O, Vander Borght T, Édeline V. Berriolo-Riedinger A, et al. Cancer Radiother. 2018 Sep;22(5):393-400. doi: 10.1016/j.canrad.2018.06.001. Epub 2018 Jul 20. Cancer Radiother. 2018. PMID: 30033076 Review.
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.
Camus V, Rossi C, Sesques P, Lequesne J, Tonnelet D, Haioun C, Durot E, Willaume A, Gauthier M, Moles-Moreau MP, Antier C, Lazarovici J, Monjanel H, Bernard S, Tardy M, Besson C, Lebras L, Choquet S, Le Du K, Bonnet C, Bailly S, Damaj G, Laribi K, Maisonneuve H, Houot R, Chauchet A, Jardin F, Traverse-Glehen A, Decazes P, Becker S, Berriolo-Riedinger A, Tilly H. Camus V, et al. Among authors: berriolo riedinger a. Blood Adv. 2021 Oct 12;5(19):3862-3872. doi: 10.1182/bloodadvances.2021004778. Blood Adv. 2021. PMID: 34461634 Free PMC article.
Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.
Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, Toubeau M, Ferrant E, Brunotte F, Casasnovas RO. Kanoun S, et al. Among authors: berriolo riedinger a. Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1735-43. doi: 10.1007/s00259-014-2783-x. Epub 2014 May 9. Eur J Nucl Med Mol Imaging. 2014. PMID: 24811577
Interim PET in Hodgkin Lymphoma: Is It So Useless?
Meignan M, Cottereau AS, Deau B, Kanoun S, Berriolo-Riedinger A, Casasnovas O. Meignan M, et al. Among authors: berriolo riedinger a. J Nucl Med. 2017 Jul;58(7):1180. doi: 10.2967/jnumed.117.190462. Epub 2017 Mar 2. J Nucl Med. 2017. PMID: 28254870 Free article. No abstract available.
Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.
Blanc-Durand P, Jégou S, Kanoun S, Berriolo-Riedinger A, Bodet-Milin C, Kraeber-Bodéré F, Carlier T, Le Gouill S, Casasnovas RO, Meignan M, Itti E. Blanc-Durand P, et al. Among authors: berriolo riedinger a. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1362-1370. doi: 10.1007/s00259-020-05080-7. Epub 2020 Oct 24. Eur J Nucl Med Mol Imaging. 2021. PMID: 33097974
51 results